md-medicaldata

Authors

 

Aleksandra Milutinović¹, Nataša Vučinić², Biljana Božin², Vojislava Bugarski Ignjatović³, Snežana Smederevac⁴, Iva Barjaktarović⁵, Jovana Drljača<sup>6

1</sup>Departman za biologiju i ekologiju, Prirodno-matematički fakultet, Univerzitet u Novom Sadu
²Katedra za farmaciju, Medicinski fakultet, Univerzitet u Novom Sadu
³Katedra za psihologiju, Medicinski fakultet, Univerzitet u Novom Sadu
⁴Odsek za psihologiju, Filozofski fakultet, Univerzitet u Novom Sadu
⁵Katedra opšteobrazovnih predmeta, Medicinski fakultet, Univerzitet u Novom Sadu
⁶Medicinski fakultet, Univerzitet u Novom Sadu

 

UDK: 616.89-008.454:575

The paper was received / Rad primljen: 25.02.2019.

Accepted / Rad prihvaćen: 06.03.2019.

 

Correspondence to:

doc. dr Nataša Vučinić,
Katedra za farmaciju,
Medicinski fakultet
Univerzitet u Novom Sadu
Hajduk Veljkova 3, 21000 Novi Sad, Srbija
e-mail: natasa.vucinic@mf.uns.ac.rs

 

 

Sažetak

 

Moždani neurotrofni faktor (BDNF) spada u proteinsku familiju neurotrofina i smatra se da je uključen u genezu određenih poremećaja raspoloženja. Polimorfizam rs6265 (Val66Met) doveden je u vezu sa kliničkom depresijom (MDD) i postoji veliki broj studija koje su ispitale ovaj odnos. Međutim, i posle mnogo godina istraživanja nije moguće utvrditi tačnu ulogu ovog polimorfizma kod MDD, te i danas ostaje otvoreno pitanje da li veza uopšte postoji i ako postoji da li je ovaj polimorfizam odgovaran za razvoj MDD ili samo njenih simptoma. Potrebno je sprovesti dalja i opsežnija istraživanja veze polimorfizma rs6265 i MDD.

 

 

Ključne reči:

moždani neurotrofni faktor, BDNF, klinička depresija, biomarker, rs6265, bihejvioralna genetika.

 

 

Abstract

 

Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin protein family and is considered to be involved in genesis of some mood disorders. Polymorphism rs6265 (Val66Met) is reported to be connected with major depressive disorder (MDD) and there is a large number of scientific papers which analyzed this connection. However, even after many years of investigation it is not possible to determine the exact role of this polymorphism in MDD, so the question if a connection between this polymorphism and MDD even exists still remains unanswered and if it exists, it is unclear whether this polymorphism entails a state marker or a trait marker. It is necessary to carry out further research related to the connection of polymorphism rs6265 and MDD.

 

Key words:

brain-derived neurotrophic factor, BDNF, major depressive disorder, biomarker, rs6265, behavioral genetics

 

 

 

References:

 

1. Smulevich, AB. Depression in general practice. Moscow:Bereg. 2000.
2. https://www.nimh.nih.gov/health/topics/depression/index.shtml, pristupljeno 15. 02. 2019.
3. Lang U, Borgwardt S. Molecular Mechanisms of Depression:Perspectives on New Treatment Strategies. Cellular physiology and biochemistry:international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013;31:761-777.
4. https://www.who.int/news-room/fact-sheets/detail/depression, pristupljeno 15.02.2019.
5. Shadrina M, Bondarenko EA, Slominsky PA. Genetics Factors in Major Depression Disease. Frontiers in Psychiatry. 2018;9:334.
6. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression:review and meta-analysis. Genetic Epidemiology. 2000;157(10):1552-62.
7. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience. 1995;15:7539–7547.
8. Lanni C, Stanga S, Racchi M, Govoni S. The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders. Current Pharmaceutical Design;2010;16(6):698-717.
9. Bothwell M. Functional interactions of neurotrophins and neurotrophins receptors. (Review). Annual Review of Neuroscience. 1995;18:223-53.
10. Binder DK, Scharfman HE. Brain-derived Neurotrophic Factor. Growth Factors. 2004;22(3):123–131.
11. Bothwell M. NGF, BDNF, NT3, and NT4. Handbook of Experimental Pharmacology 2014;220:3-15.
12. Yang B, Ren Q, Zhang J-c, Chen Q-X, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders:rethinking the brain–liver axis. Translational Psychiatry. 2017;7:e1128.
13. Cardenas-Aguayo MDC, Kazim SF, Grundke-Iqbal I, Iqbal K. Neurogenic and Neurotrophic Effects of BDNF Peptides in Mouse Hippocampal Primary Neuronal Cell Cultures. PloS one. 2013;8:e53596.
14. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders:an historical overview and future directions. Psychiatry and Clinical Neurosciences. 2010;64:341-357.
15. Matsuda N, Lu H, Fukata Y, Noritake J, Gao H, Mukherjee S, et al. Differential activity-dependent secretion of brain-derived neurotrophic factor from axon and dendrite. Journal of Neuroscience. 2009;29(45):14185–14198.
16. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Archives of Medical Science. 2015;11(6):1164–1178.
17. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nature Reviews Neuroscience. 2005;6(8):603-14.
18. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus:bidirectional transcription, complex splicing, and multiple promoters. Genomics. 2007;90(3):397-406.
19. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron. 2006;52(2) :255–269.
20. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Neuroscience 2013;14:7-23.
21. Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C. BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expression Patterns. 2006;6:941e951.
22. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiology of Aging. 2005;26:115-23.
23. Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release:implications in CNS function. Neuroscience. 2009;29(41):12764–12767.
24. Chiaruttini C, Vicario A, Li Z, Baj G, Braiuca P, Wu Y, et al. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:16481–16486.
25. Notaras M, Hill R, van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility:progress and controversy. Molecular Psychiatry 2015;20:916–930.
26. Jing D., Lee FS, Ninan I. The BDNF Val66Met polymorphism enhances glutamatergic transmission but diminishes activity-dependent synaptic plasticity in the dorsolateral striatum. Neuropharmacology. 2017;112(Pt A):84-93.
27. You J, Yuan Y, Shi Y, Zhang Z, Zhang X, Li H. Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population. Acta Neuropsychiatrica. 2009;21:186–190.
28. Bath KG, Jing DQ, Dincheva I, Neeb CC, Pattwell SS, Chao MV, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012;37:1297–1304.
29. Lee Y, Lim SW, Kim SY, Chung JW, Kim J, Myung W, et al. Association between the BDNF Val66Met polymorphism and chronicity of depression. Psychiatry Investigations. 2013;10(1):56-61.
30. Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron. 1996;16:1137–1145.
31. Glerup S, Olsen D, Vaegter CB, Gustafsen C, Sjoegaard SS, Hermey G, et al. SorCS2 regulates dopaminergic wiring and is processed into an apoptotic two-chain receptor in peripheral glia. Neuron. 2014;82:1074–1087.
32. Aldoghachi AF, Tor YS, Redzun SZ, Lokman KAB, Razaq NAA, Badamasi IM, et al. Screening of brain-derived neurotrophic factor (BDNF) single nucleotide polymorphisms and plasma BDNF levels among Malaysian major depressive disorder patients. PLOS One. 2019;14(1):e0211241.
33. Surtees PG, Wainwright NW, Willis-Owen SA, Sandhu MS, Luben R, Day NE, et al. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. Journal of psychiatric research. 2007;41(5):404–9.
34. Iga JI, Ueno SI, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, et al. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. American Journal of Medical Genetics Part B:Neuropsychiatric Genetics. 2007;144(8):1003–6.
35. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Kim YH, et al. BDNF genotype potentially modifying the association between incident stroke and depression. Neurobiology of Aging. 2008;29:789–792.
36. Choo M, Kim YK, Hwang JA, HJ Lee, Kim SH. The Association between Brain-Derived Neurotrophic Factor Gene Polymorphisms and Suicidal Behavior in Major Depression. Annals of Depression and Anxiety. 2014;1(2):1006.
37. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biological psychiatry. 2005;58:307-314.
38. Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R. Interaction between stress and the BDNF polymorphism in depression:a systematic review and meta-analysis. BMC Medicine. 2014;12:7.
39. Eisen RB., Perera S, Banfield L, Anglin R, Minuzzi L, Samaan Z Association between BDNF levels and suicidal behavior:A systematic review and meta-analysis. Systematic Reviews 2015;4:187.
40. Kishi T, Yoshimura R, Ikuta T, Iwata N. Brain-Derived Neurotrophic Factor and Major Depressive Disorder:Evidence from Meta-Analyses. Frontiers in Psychiatry. 2018;8:308.
41. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al. Genome-wide association study of major recurrent depression in the U.K population. American Journal of Psychiatry. 2010;167:949–957.
42. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. Genome-wide association study of recurrent early-onset major depressive disorder. Molecular Psychiatry. 2011;16:193–201.
43. McClearn GE. Contextual genetics. Trends in Genetics. 2006;22:314–319.
44. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Molecular Psychiatry. 2010;15:810–815.
45. Tsai SJ. Critical Issues in BDNF Val66Met Genetic Studies of Neuropsychiatric Disorders. Frontiers in Molecular Neuroscience.2018;11:156.
46. Khan MS, Wu GWY, Reus V, Hough CM, Lindquist D, Westrin A, et al. Low Serum Brain-Derived Neurotrophic Factor is associated with Suicidal Ideation in Major Depressive Disorder. Psychiatry Research. 2019;273:108–113.
47. Gonzalez-Castro, T. B., Salas-Magana, M., Juarez-Rojop, I. E., Lopez-Narvaez, M. L., Tovilla-Zarate, C. A., Hernandez-Diaz, Y. Exploring the association between BDNF Val66Met polymorphism and suicidal behavior:meta-analysis and systematic review. Journal of Psychiatric Research. 2017;94, 208–217.
48. Youssef MM, Underwood MD, Huang YY, Hsiung SC, Liu Y, Simpson NR, et al. Association of BDNF Val66Met Polymorphism and Brain BDNF Levels with Major Depression and Suicide. International Journal of Neuro­psychopharmacology.. 2018;21(6):528-538.
49. Pregelj P, Nedic G, Videtič Paska A, Zupanc T, Nikolac M, Balažić J, et al. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. Journal of Affective Disorders. 2011;128:287-290.
50. Verhagen M., van der Meij A, van Deurzen PA, Janzing JG, Arias-Vásquez A, Buitelaar JK, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder:effects of gender and ethnicity. Molecular Psychiatry. 2010;15(3):260-271.
51. Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biological Psychiatry. 2010;59:673–680.
52. Alexander N, Osinsky R, Schmitz A, Mueller E, Kuepper Y, Hennig J. The BDNF Val66Met polymorphism affects HPA-axis reactivity to acute stress. Psychoneuroendocrinology 2010;35:949–953.
53. Zhao M, Chen L, Yang J, Han D, Fang D, Qiu X, et al. BDNF Val66Met polymorphism, life stress and depression:A meta-analysis of gene-environment interaction. Journal of Affective Disorders. 2018;227:226-235.
54. Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E, et al. Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. American journal of medical genetics. Part B, Neuropsychiatric genetics :the official publication of the International Society of Psychiatric Genetics 2013;162B:183-190.
55. Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders:A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2015;55:107-118.
56. Tsai SJ. The P11, tPA/plasminogen system and brain-derived neurotrophic factor:implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants. Medical Hypotheses 2007;68:180–183.
57. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Molecular Brain Research. 2005;136:29–37.
58. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology. 1998;37(12):1553–61.
59. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLOS One. 2012;7:e42676.
61. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Gabriela Nielsen M, et al. Serum and plasma BDNF levels in major depression:a replication study and meta-analyses. The World Journal of Biological Psychiatry. 2010;11(6):763–73.
62. Colle R, Trabado S, David DJ, Brailly-Tabard S, Hardy P, Falissard B, et al. Plasma BDNF Level in Major Depression:Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients. Neuropsychobiology. 2017;75(1):39-45.
63. Lee BH, Kim YK. BDNF mRNA expression of peripheral blood mononuclear cells was decreased in depressive patients who had or had not recently attempted suicide. Journal of Affective Disorders. 2010;125:369–373.
64. Pezawas, L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. Journal of. Neuroscience. 2004;(24):10099–10102.
65. Harrisberger F, Spalek K, Smieskova R, Schmidt A, Coynel D, Milnik A, et al. The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans: a joint meta-analysis of published and new data. Neuroscience & Biobehavioral Reviews. 2014;42:267–278.
66. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. European Neuropsychopharmacology. 2010;20:535–544.
67. Ozan E, Okur H, Eker C, Eker OD, Gönül AS, Akarsu N. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Research Bulletin. 2010;81:61–65.
68. Bhang S, Ahn JH, Choi SW. Brain-derived neurotrophic factor and serotonin transporter gene-linked promoter region genes alter serum levels of brain-derived neurotrophic factor in humans. Journal of Affective Disorders. 2011;128:299–304.
69. Caldieraro MA, Vares EA, Souza LH, Spanemberg L, Guerra TA, Wollenhaupt-Aguiar B, et al. Illness severity and biomarkers in depression:Using a unidimensional rating scale to examine BDNF. Comprehensive Psychiatry. 2017;75:46-52.
70. Bus BA, Molendijk ML, Tendolkar I, Penninx BW, Prickaerts J, Elzinga BM, et al. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Molecular Psychiatry. 2015;20(5):602-8.
71. Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, et al. A method for reproducible measurements of serum BDNF:comparison of the performance of six commercial assays. Scientific reports. 2015;5:17989.
72. Mizui T, Ishikawa Y, Kumanogoh H, Lume M, Matsumoto T, Hara T, et al. BDNF pro-peptide actions facilitate hippocampal LTD and are altered by the common BDNF polymorphism Val66Met. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:E3067–E3074.
73. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, et al. C.A. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics:meta-analysis and implications. Molecular Psychiatry. 2015;20(9):1108-19.
74. Ihara K, Yoshida H, Jones PB, Hashizume M, Suzuki Y, Ishijima H, et al. Serum BDNF levels before and after the development of mood disorders:a case-control study in a population cohort. Translational Psychiatry. 2016;12(6):e782.
75. Chen MJ. Should You be Genotyped for the BDNF Val66Met Polymorphism? EC Neurology. 2017;8(5):125-128.

PDF Milutinović A. et al • MD-Medical Data 2019;11(1): 049-054